Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: RéunionFázis nélkül

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

A legfontosabb adatok

Ki végzi
Physio-Assist
Hol
Saint-Denis és Saint-Pierre (Réunion)Mind a 2 helyszín megnézéseMég 5 másik országban, 55 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
468 fő, tervezett
Kezdés
2025. febr. 3.
Várható befejezés
2028. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • SIMEOX
  • Remote Physiotherapy
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek nem cisztás fibrózis okozta bronchiectasiájuk van, rendszeresen köpetet ürítenek, és az elmúlt időben légúti rosszullétük (exacerbációjuk) volt. A SIMEOX légúttisztító eszközt otthon, távfizioterápiával együtt vizsgálják.

Életkor
18 évesnél idősebb
Nem
Férfiak és nők
A betegség stádiuma
Nem cisztás fibrózis okozta bronchiectasia, amelyet CT-vizsgálat igazolt. Klinikailag stabil állapot: az utolsó exacerbáció vége óta legalább 4 hét telt el, és a betegséget módosító kezelés 4 hete nem változott.
Korábbi kezelés
Az elmúlt 12 hónapban legalább 2 tüdőexacerbáció, amely miatt módosítani kellett a kezelést, vagy legalább 1, amely kórházi kezelést igényelt. Aki otthon már használ SIMEOX-ot, mellkasi rezgőmellényt (HFCWO) vagy IPV-t, nem vehet részt.

A részvétel fő kizáró okai

  • Cisztás fibrózis
  • Aktív dohányzás
  • Elsősorban COPD vagy asztma, megfelelő bronchiectasia nélkül
  • Instabil szívproblémák
  • Terhesség vagy szoptatás

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female aged over 18 years
  • Predominant diagnosis of Non CF bronchiectasis disease, excluding cystic fibrosis, confirmed by computed tomography (CT)
  • Regular and chronic sputum production
  • Clinically stable at inclusion; Defined by a delay of at least 4 weeks since the end of the last exacerbation according to the European consensus (Hill, European Respiratory Journal, 2017); No change in disease-modifying treatment for 4 weeks
  • Having had at least two pulmonary exacerbations in the 12 months prior to inclusion and having required a change in specific treatment for these exacerbations; Or Having had at least one pulmonary exacerbation in the 12 months prior to inclusion requiring hospitalisation
  • Considered by the investigator to be physically and psychologically able to use the device and carry out the procedures under study
  • Patient covered by a social security system, when applicable in the concerned country

Ki nem vehet részt

  • Predominant diagnosis of Chronic obstructive pulmonary disease (COPD) or asthma, traction bronchiectasis, bronchiectasis resulting from focal endobronchial lesion, sarcoidosis or active allergic bronchopulmonary aspergillosis; However, patients with COPD or asthma and concomitant bronchiectasis may be eligible if they present symptoms of bronchiectasis (e. g. persistent cough, excessive mucus production, fatigue, shortness of breath, chest pain, etc.) and meet the following conditions:
  • For patients with asthma: documented evidence of bronchiectasis exacerbations (e.g., increased sputum production, sputum purulence, or infective exacerbation) requiring treatment with antibiotics, rather than exacerbation predominantly caused by bronchospasm or loss of asthma control; Active smoking; Suspected (but undiagnosed) or unstabilised immune deficiency (at investigator's discretion); In the case of long-term immunosuppressive treatment, risk of discontinuation of this treatment during the study; Unstable cardiovascular pathologies (acute coronary syndrome, unstable angina pectoris, uncontrolled rhythm disorders, unstable heart failure); Haemodynamic instability; Uncontrolled gastro-oesophageal reflux (persistence of symptoms despite treatment), at investigator's discretion; Acute pneumothorax or increased susceptibility to pneumothorax/pneumomediastinum; Inability to cough vigorously and independently, at investigator's discretion; Had a significant episode of haemoptysis in the 6 weeks prior to inclusion, at the discretion of the investigator; Patient using an endotracheal tube, tracheostomy tube or daytime ventilation >16h with a mask; Patients with neuromuscular disease and respiratory muscle weakness, at the discretion of the investigator; Recent cardiothoracic surgery, including oesophageal surgery within 3 months of inclusion; Severe acute lung injury or barotrauma within 3 months of inclusion; Difficulty in evacuating secretions from the upper airways due to weakness of the respiratory muscles, or of the oropharyngeal or buccal musculature, at the discretion of the investigator; Risk of airway aspiration, e.g. from tube feeding or recent meals, at investigator's discretion; Inspiratory muscle weakness with inability to tolerate increased work of breathing, at investigator's discretion; Severe restrictive disease (Total Lung Capacity < 60% with complete plethysmography); Bullous emphysema; Participation in other interventional clinical study in the month prior to inclusion or during the study period; Patient unavailable or wishing to move to a region where the protocol is not present before the end of their participation; Vulnerable people:; pregnant women (verified by a urine or blood human chorionic gonadotropin (HCG) test for all women wishing to participate in the protocol and of childbearing age, without contraception), breastfeeding mothers or women planning to become pregnant during the period of participation in the clinical investigation; a person deprived of liberty by judicial or administrative decision; a person subject to a legal protection measure
  • Patients using one of the following motorised mechanical bronchial drainage devices at home at the time of inclusion:; SIMEOX,; an extra-thoracic high-frequency chest wall oscillation device (HFCWO) (The Vest,...); intrapulmonary percussion ventilation (IPV)
  • Patients who have been using a powered mechanical cough aid at home for less than a year at the time of inclusion:; a mechanical in-exsufflator (MI E) such as the Cough Assist; a pressure reducer such as the Alpha300
  • Cystic fibrosis
  • For patients with COPD: bronchiectasis affecting at one or more pulmonary segment in at least two pulmonary lobes, as defined by the EMBARK group COPD-bronchiectasis association criteria (ROSE criteria)

Helyszínek itt: Réunion

Még 5 másik országban, 55 helyszínen

  • CHU La Réunion Félix GuyonSaint-Denis, RéunionContact: Pauline Périnet-MarquetRésztvevőt keres
  • CHU La Réunion SudSaint-Pierre, RéunionContact: Pauline Périnet-MarquetRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Bronchiectasis is a chronic lung disease of multiple aetiologies characterised by permanent dilatation of the calibre of a territory of the bronchial tree with impaired mucociliary clearance. This alteration causes mucus retention, leading to infections and chronic bronchial inflammation. Respiratory physiotherapy is one of the cornerstones of the management of these patients, in particular to facilitate bronchial drainage. In patients with abundant bronchial secretions, it is recommended that bronchial drainage sessions be carried out on a daily or more frequent basis, which represents a very substantial burden in terms of care. In addition, access to respiratory physiotherapy is not always easy for patients due to geographical or time constraints or the availability of professionals. Moreover, few professionals are trained in this specific care for chronic lung diseases.

A teljes eredeti leírásKevesebb

SIMEOX (Physio-Assist, France) is an innovative medical device (CE medical mark) for draining the bronchial tree. By means of a mouthpiece, this device generates a succession of very short intermittent negative air pressure pulses which disseminate a pneumatic vibratory signal in the patient's bronchial tree, modifying the rheological properties of the mucus, facilitating the mobilisation of secretions and assisting their transport towards the upper airways.

A recent pilot study demonstrated that the use of SIMEOX independently by the patient at home for 3 months, combined with remote Physiotherapy (1 session/2 weeks), provided a very satisfactory bronchial drainage solution for patients (satisfaction assessed at 9/10 by visual analogue scale), with an improvement in their quality of life and very good compliance with the device (median of 4.7 sessions/week).

This bronchial drainage strategy requires a long-term assessment.

Hypothesis: the use of SIMEOX independently by the patient at home could improve long-term quality of life and reduce the rate of pulmonary exacerbations in non-cystic fibrosis (non-CF) patients with bronchiectasis (bronchial dilatation) in comparison to Standard of Care (SoC).

A vizsgálat 2 csoportja

  • ControlEgyéb csoport

    Remote Physiotherapy + standard of care

    Kezelés: Remote Physiotherapy

  • SIMEOXA vizsgált kezelés

    SIMEOX device combined with Remote Physiotherapy + standard of care

    Kezelés: SIMEOX és Remote Physiotherapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Impact of SIMEOX Airway Clearance Medical Device at Home, Combined With Remote Physiotherapy, on Quality of Life and Pulmonary Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis, Compared With Enhanced Standard of Care
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. november 2.